Measles antibody prevalence rates among young adults in Israel.

Medical Corps, Israel Defense Forces, Rehovet, Israel.
American Journal of Infection Control (Impact Factor: 2.33). 06/2002; 30(3):165-9. DOI: 10.1067/mic.2002.118617
Source: PubMed

ABSTRACT In Israel, vaccination coverage against measles is high, yet seroepidemiologic studies have shown that more than 15% of the 18-year-old population were unprotected against the disease. A 2-dose program of vaccination against measles, mumps, and rubella at the ages of 1 and 6 years was begun in 1990, supplemented by a measles catch-up plan for all 13-year-olds. The aim of this study was to assess the prevalence of antimeasles antibodies at induction to the Israel Defense Forces in the first doubly vaccinated birth-cohort.
In 1996, serum samples of 540 recruits, 339 men and 201 women, were tested for measles virus antibody. Findings were compared with surveys conducted in 1987 and 1990.
Measles antibodies were present in 95.6% (95% CI, 93.5-97.1) of the recruits. Antibody prevalence was higher in women than in men (99% vs 93.5%; P =.0096). A slightly lower seroprevalence was found in recruits born in the former Soviet Union. The results were substantially higher than the seroprevalence rates found in 1987 (73.3%) and 1990 (84.6%).
The high prevalence of antimeasles antibodies in the young adult population in Israel points to the success of the double-vaccination policy in promoting immunity against the disease.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The transfer of Measles specific IgG antibody was assessed in 128 sera of infants and 30 sera of mother-child pairs at delivery. The 158 infants were within the age range of birth to 9 months. Of the 30 serum samples of mother to child pairs, 30(100%) of the mothers had the antibody but only 28(93.3%) passed the antibody to their newborn which means 2(6.7%) of the infants did not acquire the antibody. In the 158 serum samples of infants tested 44.8% (71) were seropositive which means they acquired the antibody while 55.1% (87) were susceptible to measles virus. The result indicates that with increase in age, the percentage susceptibility of infant increases. The antibody level is high (77.8%) in one day olds and none (0%) in 9 months infants. This shows that infants at late ages before vaccination are susceptible to the measles virus. In conclusion, the result shows that infants within the age of 0 to 3 months have a higher level of antibody than other ages. Hence, susceptibility to measles virus in infants within the ages of 7 to 9 months is high.
  • Source
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Aims: A survey was conducted amongst university students to assess their level of susceptibility to and knowledge about measles, mumps and rubella (MMR) and their prevention, and to find factors associated to their seropositivity for MMR viruses. Subjects, and methods: A cross-sectional study was conducted involving 961 students from the University of Cassino (Italy). The enzyme immunoassay method was used to assess seropositivity for MMR, while knowledge and previous vaccination information were acquired through a self-administered questionnaire. Results: The prevalence of IgG antibodies was 93.2% for measles, 91.4% for mumps and 81.3% for rubella. The susceptibility for measles was higher in the 21–25 and over 31 age groups. The seroprevalence profile of mumps was similar to that of measles, while the level of immunity to rubella was very low in students aged under 20 years (76.7%) and 21–25 years (81.2%). Only 111 students said they had been vaccinated against measles, 46 against mumps and 103 against rubella. Most students demonstrated poor knowledge concerning MMR and were not practicing preventive behaviours. Conclusions: The susceptibility was particularly high for rubella. Concerted efforts are needed to educate young adults about the benefits of vaccination and to raise their level of consciousness so as to motivate them to request vaccination.
    Journal of Public Health 10/2010; 18(5). DOI:10.1007/s10389-010-0324-z · 2.06 Impact Factor